Engineers at the University of Pennsylvania and Rice University have refined a technology for editing individual genetic “base pairs” to a new level of precision, opening the door to safer, more reliable therapies for a wide range of genetic diseases, and to potential treatments for some cystic fibrosis patients that may yield better outcomes than existing therapies.